

Clinical Criteria

Subject: Abraxane (paclitaxel, protein bound)

Document #: ING-CC-0099 **Publish Date:** 03/23/202006/15/2020

Status: Revised **Last Review Date:** 02/21/202005/15/2020

Table of Contents

[Overview](#) [Coding](#) [References](#)

[Clinical criteria](#) [Document history](#)

Overview

This document addresses the use of protein/albumin bound paclitaxel (Abraxane). Abraxane is a taxane primarily used to treat breast cancer, pancreatic cancer, and non-small cell lung cancer.

The FDA approved indications for Abraxane include:

- Metastatic breast cancer after failure of combination chemotherapy
- Non-small cell lung cancer (NSCLC) as first line treatment of locally advanced or metastatic NSCLC in combination with carboplatin
- Adenocarcinoma of the pancreas as first line therapy of metastatic disease in combination with gemcitabine

The National Comprehensive Cancer Network® (NCCN) provides additional recommendations with a category 1 or 2A level of evidence for the following:

- Use in the treatment of taxane responsive cancers when there is incidence of solvent-based taxane hypersensitivity including in NSCLC, endometrial cancers, breast cancers and solid tumors
- Use for locally advanced or metastatic NSCLC in combination with carboplatin and pembrolizumab or atezolizumab.
- Use for ovarian cancer in the treatment of persistent or recurrent ovarian cancer

Abraxane label includes a black box warning restricting use in patients with baseline neutrophil counts of less than 1,500 cells/mm³, and frequent peripheral blood cell counts should be performed to monitor for bone marrow suppression.

Other Uses

Protein-bound paclitaxel has been studied or is currently being studied as a single agent or in combination with other chemotherapeutic agents for the treatment of other cancers, including use as first-line therapy for HER2-negative metastatic breast cancer (Lobo, 2010; Mirtsching, 2011), adrenocortical cancer (Demeure, 2012), advanced solid tumors (Abu-Khalaf, 2015), angiosarcoma (Hirata, 2011), cancer of unknown primary (CUP), cervical cancer (Alberts, 2012; Li, 2017), esophageal cancer (Fan, 2016; Shi, 2013), gastric cancer (Koizumi, 2015), head and neck cancer (including squamous-cell carcinoma of the esophagus, hypopharynx, nasopharyngeal, oropharynx, and oral cavity) (Adkins, 2013; Adkins, 2016; Damascelli, 2007; Huang, 2016), hepatocellular cancer, prostate cancer (Shepard, 2009), small cell lung cancer (Grilley-Olson, 2015), urothelial cancer (Ko, 2013), AIDS-related Kaposi Sarcoma (Fortino, 2016), and small bowel adenocarcinoma (Aldrich, 2018; Overman, 2015). Limitations of some of these studies include lack of a randomized comparator group and small study populations. To date, the FDA has not approved protein-bound paclitaxel for use in the treatment of any of these conditions. NCCN also gives a category 2A recommendation for use of Abraxane in combination with atezolizumab, carboplatin, and with or without bevacizumab as first line therapy in those with NSCLC and BRAF or NTRK positive tumors in certain circumstances, however, published data is lacking. Additionally, the NCCN NSCLC guideline discussion emphasizes the importance of targeted therapies in individuals with specific oncogenic drivers (i.e., EGFR, ALK, ROS1, BRAF, NTRK).

Definitions and Measures

Adenocarcinoma: Cancer originating in cells that line specific internal organs and that have gland-like (secretory) properties.

Adjuvant therapy: Treatment given after the primary treatment to increase the chances of a cure; may include chemotherapy, radiation, hormone or biological therapy.

Chemotherapy: Medical treatment of a disease, particularly cancer, with drugs or other chemicals.

ECOG or Eastern Cooperative Oncology Group Performance Status: A scale and criteria used by doctors and researchers to assess how an individual's disease is progressing, assess how the disease affects the daily living abilities of the individual, and determine appropriate

treatment and prognosis. This scale may also be referred to as the WHO (World Health Organization) or Zubrod score which is based on the following scale:

- 0 = Fully active, able to carry on all pre-disease performance without restriction
- 1 = Restricted in physically strenuous activity but ambulatory and able to carry out work of a light or sedentary nature, for example, light house work, office work
- 2 = Ambulatory and capable of all self-care but unable to carry out any work activities. Up and about more than 50% of waking hours
- 3 = Capable of only limited self-care, confined to bed or chair more than 50% of waking hours
- 4 = Completely disabled. Cannot carry on any self-care. Totally confined to bed or chair
- 5 = Dead

Line of Therapy:

- First-line therapy: The first or primary treatment for the diagnosis, which may include surgery, chemotherapy, radiation therapy or a combination of these therapies.
- Second-line therapy: Treatment given when initial treatment (first-line therapy) is not effective or there is disease progression.
- Third-line therapy: Treatment given when both initial (first-line therapy) and subsequent treatment (second-line therapy) are not effective or there is disease progression.

Locally advanced cancer: Cancer that has spread only to nearby tissues or lymph nodes.

Malignant: Cancerous. Malignant cells can invade and destroy nearby tissue and spread to other parts of the body.

Melanoma: A type of cancer that begins in the melanocytes. Melanoma is also referred to as malignant melanoma and cutaneous melanoma.

Microtubule inhibitors (MTI): A class of drugs including taxanes, vinca alkaloids, and epothilones that stabilize or destabilize microtubules, thereby suppressing microtubule dynamics required for proper mitotic function, effectively blocking cell cycle progression and resulting in cell death.

Non-small cell lung cancer: A group of lung cancers that are named for the kinds of cells found in the cancer and how the cells look under a microscope. The three main types of non-small cell lung cancer are squamous cell carcinoma, large cell carcinoma, and adenocarcinoma.

One line of therapy: Single line of therapy.

Refractory Disease: Illness or disease that does not respond to treatment.

Relapse or recurrence: After a period of improvement, during which time a disease (for example, cancer) could not be detected, the return of signs and symptoms of illness or disease. For cancer, it may come back to the same place as the original (primary) tumor or to another place in the body.

Taxane: A type of mitotic inhibitor and antimicrotubule drug used to treat cancer that blocks cell growth by stopping mitosis (cell division).

Unresectable: Unable to be removed with surgery.

Clinical Criteria

When a drug is being reviewed for coverage under a member's medical benefit plan or is otherwise subject to clinical review (including prior authorization), the following criteria will be used to determine whether the drug meets any applicable medical necessity requirements for the intended/prescribed purpose.

Abraxane (paclitaxel, protein bound)

Requests for Abraxane (paclitaxel, protein bound) may be approved for the treatment of any of the following indications:

- I. Relapsed or metastatic breast cancer when the following criteria are met (NCCN2A):
 - A. Used as a single agent; **AND**
 - B. Used in a single line of therapy;
- OR**
- II. Metastatic or unresectable locally advanced breast cancer when the following criteria are met (NCCN 2A);
 - A. Individual has triple-negative breast cancer, defined as lack of estrogen- and progesterone-receptor expression and no overexpression of HER2; **AND**
 - B. Using as first line treatment; **AND**
 - C. Individual is using in combination with atezolizumab;

- OR**
- III. Treatment of any breast cancer in an individual with confirmed taxane (that is, solvent-based paclitaxel or docetaxel) hypersensitivity (NCCN 2A);
- OR**
- IV. Malignant Melanoma when the following criteria are met (NCCN 2A):
- Used as a single agent; **AND**
 - Individual is using as second line or subsequent therapy; **AND**
 - Individual has an ECOG performance status of 0-2(Kottschade 2011);
- OR**
- V. Treatment of locally advanced or metastatic NSCLC when the following criteria are met:
- Used as first-line therapy; **AND**
 - Given in combination with carboplatin;
- OR**
- VI. Treatment of locally advanced or metastatic squamous NSCLC when **all** of the following criteria are met (NCCN 1, NCCN 2A):
- Used as first-line therapy; **AND**
 -
 - Given in combination with carboplatin **and** pembrolizumab; **AND**
 - Individual has a current ECOG performance status of 0-2;
- OR**
- VII. Treatment of recurrent, advanced, or metastatic nonsquamous NSCLC when the following criteria are met (~~Tecentriq 2019~~NCCN 2A):
- Used as first-line therapy; **AND**
 - Given in combination with atezolizumab and carboplatin; **AND**
 - Confirmation of EGFR, and ALK, ROS1, and BRAF mutations that are negative or unknown;
- OR**
- VIII. Treatment of recurrent, advanced, or metastatic nonsquamous NSCLC when the following criteria are met (NCCN 1, 2A):
- Used as subsequent therapy after failure of kinase inhibitor targeted agent; **AND**
 - Given in combination with carboplatin and atezolizumab;
- OR**
- IX-X. Treatment of NSCLC in an individual with confirmed taxane (that is, solvent-based paclitaxel or docetaxel) hypersensitivity (NCCN 2A);
- OR**
- IX-X. Ovarian Cancer (Epithelial Ovarian Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer) when the following criteria are met (NCCN 2A):
- Treatment of persistent or recurrent ovarian cancer when used as a single agent (epithelial ovarian cancer, fallopian tube cancer, or primary peritoneal cancer); **OR**
 - Treatment of persistent or recurrent ovarian cancer when used with carboplatin (epithelial ovarian cancer, fallopian tube cancer, or primary peritoneal cancer) in an individual with confirmed taxane (that is, solvent-based paclitaxel or docetaxel) hypersensitivity;
- OR**
- X-XI. Locally advanced or metastatic adenocarcinoma of the pancreas when the following criteria are met (Label, NCCN 2A):
- Used as first-line therapy or later; **AND**
 - Given in combination with gemcitabine as a single-line of therapy;
- OR**
- XI-XII. Recurrent, metastatic, or high-risk endometrial cancer in an individual with confirmed taxane (that is, solvent-based paclitaxel or docetaxel) hypersensitivity (NCCN 2A);
- OR**
- XII-XIII. Solid tumors where treatment with a taxane is medically appropriate and the individual has confirmed taxane (that is, solvent-based paclitaxel or docetaxel) hypersensitivity (NCCN 2A).

Formatted: Font: Bold

Formatted: Left

Formatted: Left, Indent: Left: 0.65", No bullets or numbering

Formatted: Left, Indent: Left: 0.19", No bullets or numbering, Tab stops: 0.19", Left + Not at 0.65" + 0.65"

Formatted: Font: Bold

Abraxane (paclitaxel, protein bound) may not be approved for the following:

- Individual has baseline neutrophil count of less than 1,500 cells/mm³ prior to initiation of Abraxane; **OR**
- When the above criteria are not met and for all other indications.

Coding

The following codes for treatments and procedures applicable to this document are included below for informational purposes. Inclusion or

exclusion of a procedure, diagnosis or device code(s) does not constitute or imply member coverage or provider reimbursement policy. Please refer to the member's contract benefits in effect at the time of service to determine coverage or non-coverage of these services as it applies to an individual member.

HCPCS

J9264	Injection, paclitaxel protein-bound particles, 1 mg [Abraxane]
-------	--

ICD-10 Diagnosis

C00.0-C80.2	Malignant neoplasms
C34.0-C34.92	Malignant neoplasm of bronchus and lung
C50.0-C50.3	Malignant neoplasm of breast
C54.0-C54.8	Malignant neoplasm of endometrium
C56.0-C56.9	Malignant neoplasm of ovary
D00.0-D09.9	In-situ neoplasms
Z85.00-Z85.59	Personal history of malignant neoplasm
Z85.810-Z85.9	Personal history of malignant neoplasm

Document History

Revised: 05/15/2020

Document History:

- 05/15/2020 – Select Review: Update NSCLC criteria to include first-line therapy use in recurrent and advanced disease, and confirmation of negative ROS1 and BRAF mutations when using in combination with atezolizumab and carboplatin. Add criteria to allow use as subsequent therapy in NSCLC after failure of targeted agents. Coding reviewed: No changes.
- 02/21/2020 – Annual Review: Update NSCLC criteria to remove use with cisplatin per NCCN update. Update ovarian cancer criteria to add use with carboplatin if individual has solvent-base paclitaxel or docetaxel hypersensitivity. Add baseline neutrophil count threshold in non-approvable criteria per labeled contraindications. Wording and formatting changes. Coding Review: No changes.
- 12/09/2019 – Select Review: Add criteria for metastatic nonsquamous NSCLC in combination with atezolizumab and carboplatin. Coding reviewed: Added ICD-10 DX C34.0-C56.9
- 08/16/2019 – Select Review: Update to clarify single agent use in ovarian cancer. Wording and formatting changes for consistency. Coding Reviewed: No changes.
- 05/17/2019 – Annual Review: Initial review of protein bound paclitaxel (Abraxane); Updated to clarify that use in combination with pembrolizumab for the treatment of NSCLC required that the individual also meet the criteria for pembrolizumab. Coding Reviewed: No changes.

References

1. Abu-Khalaf MM, Baumgart MA, Gettinger SN, et al. Phase 1b study of the mammalian target of rapamycin inhibitor sirolimus in combination with nanoparticle albumin-bound paclitaxel in patients with advanced solid tumors. Cancer. 2015; 121(11):1817-1826.
2. Adkins D, Ley J, Michel L, et al. Nab-paclitaxel, cisplatin, and 5-fluorouracil followed by concurrent cisplatin and radiation for head and neck squamous cell carcinoma. Oral Oncol. 2016; 61:1-7.
3. Adkins D, Ley J, Trinkaus K, et al. A phase 2 trial of induction nab-paclitaxel and cetuximab given with cisplatin and 5-fluorouracil followed by concurrent cisplatin and radiation for locally advanced squamous cell carcinoma of the head and neck. Cancer. 2013; 119(4):766-773.
4. Alberts DS, Blessing JA, Landrum LM, et al. Phase II trial of nab-paclitaxel in the treatment of recurrent or persistent advanced cervix cancer: a gynecologic oncology group study. Gynecol Oncol. 2012; 127(3):451-455.
5. Aldrich JD, Raghav KPS, Varadhachary GR, et al. Retrospective analysis of taxane-based therapy in small bowel adenocarcinoma. Oncologist. 2019;24:e384-6.
6. Clinical Pharmacology [database online]. Tampa, FL: Gold Standard, Inc.: 2019. URL: <http://www.clinicalpharmacology.com>. Updated periodically.
7. DailyMed. Package inserts. U.S. National Library of Medicine, National Institutes of Health website. <http://dailymed.nlm.nih.gov/dailymed/about.cfm>. Accessed: December 17, 2019.
8. Damascelli B, Patelli G, Ticha V, et al. Feasibility and efficacy of percutaneous transcatheter intraarterial chemotherapy with paclitaxel in albumin nanoparticles for advanced squamous-cell carcinoma of the oral cavity, oropharynx, and hypopharynx. J Vasc Interv Radiol. 2007; 18(11):1395-1403.
9. Demeure MJ, Stephan E, Sinari S, et al. Preclinical investigation of nanoparticle albumin-bound paclitaxel as a potential treatment for adrenocortical cancer. Ann Surg. 2012; 255(1):140-146.
10. DrugPoints® System [electronic version]. Truven Health Analytics, Greenwood Village, CO. Updated periodically.

11. Fan Y, Jiang Y, Zhou X, et al. Phase II study of neoadjuvant therapy with nab-paclitaxel and cisplatin followed by surgery in patients with locally advanced esophageal squamous cell carcinoma. *Oncotarget*. 2016; 7(31):50624-50634.
12. Fortino S, Santoro M, Iuliano E, et al. Treatment of Kaposi's Sarcoma (KS) with nab-paclitaxel. *Ann Oncol* 2016;27:suppl_4: iv124.
13. Grilley-Olson JE, Keedy VL, Sandler A, et al. A randomized phase II study of carboplatin with weekly or every-3-week nanoparticle albumin-bound paclitaxel (Abraxane) in patients with extensive-stage small cell lung cancer. *Oncologist*. 2015; 20(2):105-106.
14. Hirata T, Yonemori K, Ando M, et al. Efficacy of taxane regimens in patients with metastatic angiosarcoma. *Eur J Dermatol*. 2011; 21(4):539-545.
15. Huang Y, Liang W, Yang Y, et al. Phase I/II dose-finding study of nanoparticle albumin-bound paclitaxel (nab®-paclitaxel) plus cisplatin as treatment for metastatic nasopharyngeal carcinoma. *BMC Cancer*. 2016; 16:464.
16. Koizumi W, Morita S, Sakata Y. A randomized Phase III trial of weekly or 3-weekly doses of nab-paclitaxel versus weekly doses of Cremophor-based paclitaxel in patients with previously treated advanced gastric cancer (ABSOLUTE Trial). *Jpn J Clin Oncol*. 2015; 45(3):303-306.
17. Kottschade LA, Suman VJ, Amatruda T 3rd, et al. A phase II trial of nab-paclitaxel (ABI-007) and carboplatin in patients with unresectable stage IV melanoma: a North Central Cancer Treatment Group Study, N057E(1). *Cancer*. 2011; 117(8):1704-1710.
18. Ko YJ, Canil CM, Mukherjee SD, et al. Nanoparticle albumin-bound paclitaxel for second-line treatment of metastatic urothelial carcinoma: a single group, multicentre, phase 2 study. *Lancet Oncol*. 2013; 14(8):769-776.
19. Lexi-Comp ONLINE™ with AHFS™, Hudson, Ohio: Lexi-Comp, Inc.; 2019; Updated periodically.
20. Li Y, Zeng J, Huang M, et al. A phase 2 study of nanoparticle albumin-bound paclitaxel plus nedaplatin for patients with advanced, recurrent, or metastatic cervical carcinoma. *Cancer*. 2017; 123(3):420-425.
21. Lobo C, Lopes G, Baez O, et al. Final results of a phase II study of nab-paclitaxel, bevacizumab, and gemcitabine as first-line therapy for patients with HER2-negative metastatic breast cancer. *Breast Cancer Res Treat*. 2010; 123(2):427-435.
22. Mirtsching B, Cosgriff T, Harker G, et al. Phase II study of weekly nanoparticle albumin-bound paclitaxel with or without trastuzumab in metastatic breast cancer. *Clin Breast Cancer*. 2011; 11(2):121-128.
23. NCCN Clinical Practice Guidelines in Oncology™. © 2020 National Comprehensive Cancer Network, Inc. For additional information visit the NCCN website: <http://www.nccn.org/index.asp>. Accessed on April 17, 2020.
 - a. AIDS-related Kaposi Sarcoma. V2.2019. Revised November 29, 2018.
 - b. Breast cancer. V3.2019. Revised September 6, 2019.
 - c. Cutaneous Melanoma. V1.2020. Revised December 19, 2019.
 - d. Hepatobiliary Cancers. V3.2019. Revised August 1, 2019.
 - e. Non-Small cell lung cancer. V3.2020. Revised February 11, 2020.
 - f. Ovarian Cancer, including fallopian tube cancer and primary peritoneal cancer. V3.2019. Revised November 26, 2019.
 - g. Pancreatic Adenocarcinoma. V1.2020. Revised November 26, 2019.
 - h. Small Bowel Adenocarcinoma. V1.2020. Revised July 30, 2019.
 - i. Uterine Neoplasms. V4.2019. Revised September 16, 2019.
 - j. Uveal melanoma. V1.2019. Revised June 14, 2019.
24. Overman MJ, Adam L, Raghav K, et al. Phase II study of nab-paclitaxel in refractory small bowel adenocarcinoma and CpG island methylator phenotype (CIMP)-high colorectal cancer. *Ann Oncol*. 2018;29:139-44.
25. Shepard DR, Dreicer R, Garcia J, et al. Phase II trial of neoadjuvant nab-paclitaxel in high risk patients with prostate cancer undergoing radical prostatectomy. *J Urol*. 2009; 181(4):1672-1677; discussion 1677.
26. Shi Y, Qin R, Wang ZK, Dai GH. Nanoparticle albumin-bound paclitaxel combined with cisplatin as the first-line treatment for metastatic esophageal squamous cell carcinoma. *Onco Targets Ther*. 2013; 6:585-591.
27. Tecentriq® (atezolizumab) [Product Information]. San Francisco: Genentech, Inc. Accessed on December 5, 2019.
28. West H, McCleod M, Hussein M, et al. Atezolizumab in combination with carboplatin plus nab-paclitaxel chemotherapy compared with chemotherapy alone as first-line treatment for metastatic non-squamous non-small-cell lung cancer (IMpower130): a multicentre, randomised, open-label, phase 3 trial. *Lancet Oncol*. 2019 Jul;20(7):924-937. Epub 2019 May 20.

Federal and state laws or requirements, contract language, and Plan utilization management programs or policies may take precedence over the application of this clinical criteria.

No part of this publication may be reproduced, stored in a retrieval system or transmitted, in any form or by any means, electronic, mechanical, photocopying, or otherwise, without permission from the health plan.

© CPT Only – American Medical Association